OUR VISION
We See a Future Free of Bleeding Disorders
We are a nonprofit organization devoting its efforts to improving the quality of life for persons affected with bleeding disorders and their complications. This mission is accomplished through outreach development, educational programs, informational literature, support services and patient referrals. HFM is a proud member of the Hemophilia Federation of America.
Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE®
Important Community Notice from the Hemophilia Foundation of Maryland Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE® Takeda has announced its decision to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. Takeda recognizes the significant impact this decision may have on patients who rely on these medications and is committed to supporting the community throughout this transition. Product Availability and Transition Plans Takeda will continue to supply HEMOFIL M and RECOMBINATE until inventory is
About This Website
HFM wants to help ...
Through advocacy, education, outreach development, support services and the relentless pursuit of a cure, we aim to improve the lives of individuals in Maryland affected by hemophilia, vWD and other bleeding disorders.
Hemophilia Foundation of Maryland (HFM)
13 Class Court Parkville, MD 21234
Who we are
The Hemophilia Foundation of Maryland evolved in the early 1950’s from a group of concerned families who were affected by a hemophilia diagnosis.
These early chapter families were brought together by the social worker at St. Agnes Hospital, where most were treated. Some of the founding members of this organization continue to guide HFM today.
OUR VISION
We See a Future Free of Bleeding Disorders
We are a nonprofit organization devoting its efforts to improving the quality of life for persons affected with bleeding disorders and their complications. This mission is accomplished through outreach development, educational programs, informational literature, support services and patient referrals. HFM is a proud member of the Hemophilia Federation of America.Click a section below to begin ...
Through advocacy, education, organization and the relentless pursuit of a cure and increased research funding, we aim to improve the lives of individuals in Maryland affected by hemophilia, vWD and other bleeding disorders.
Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE®
Important Community Notice from the Hemophilia Foundation of Maryland Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE® Takeda has announced its decision to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. Takeda recognizes the significant impact this decision may have on patients who rely on these medications and is committed to supporting the community throughout this transition. Product Availability and Transition Plans Takeda will continue to supply HEMOFIL M and RECOMBINATE until inventory is
Subscribe to HFM Updates
Keep in touch with our latest happenings …
